Research Analysts Issue Forecasts for CLOV Q2 Earnings

Clover Health Investments, Corp. (NASDAQ:CLOV - Free Report) - Analysts at Leerink Partnrs issued their Q2 2025 earnings per share (EPS) estimates for Clover Health Investments in a research note issued on Wednesday, May 7th. Leerink Partnrs analyst W. Mayo forecasts that the company will earn $0.03 per share for the quarter. The consensus estimate for Clover Health Investments' current full-year earnings is ($0.12) per share. Leerink Partnrs also issued estimates for Clover Health Investments' Q3 2025 earnings at $0.03 EPS, Q4 2025 earnings at $0.00 EPS, FY2025 earnings at $0.11 EPS, Q1 2026 earnings at $0.05 EPS, Q3 2026 earnings at $0.06 EPS, Q4 2026 earnings at $0.00 EPS, FY2026 earnings at $0.18 EPS, FY2027 earnings at $0.24 EPS, FY2028 earnings at $0.28 EPS and FY2029 earnings at $0.32 EPS.

Clover Health Investments (NASDAQ:CLOV - Get Free Report) last released its earnings results on Tuesday, May 6th. The company reported $0.05 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.07) by $0.12. The company had revenue of $462.33 million during the quarter, compared to analyst estimates of $466.93 million. Clover Health Investments had a negative return on equity of 25.46% and a negative net margin of 5.92%.

Separately, Canaccord Genuity Group upped their price objective on Clover Health Investments from $4.20 to $4.50 and gave the company a "buy" rating in a research note on Monday, March 3rd.

Clover Health Investments Stock Up 1.9%

Clover Health Investments stock traded up $0.07 during trading on Monday, hitting $3.48. The stock had a trading volume of 1,782,880 shares, compared to its average volume of 6,676,057. Clover Health Investments has a 1 year low of $0.86 and a 1 year high of $4.87. The stock's 50 day moving average is $3.55 and its two-hundred day moving average is $3.70. The stock has a market cap of $1.78 billion, a price-to-earnings ratio of -17.37 and a beta of 1.99.

Institutional Investors Weigh In On Clover Health Investments

Several institutional investors have recently made changes to their positions in CLOV. Barclays PLC purchased a new stake in shares of Clover Health Investments during the third quarter worth $298,000. JPMorgan Chase & Co. purchased a new stake in shares of Clover Health Investments during the third quarter worth $448,000. Graypoint LLC purchased a new stake in shares of Clover Health Investments during the fourth quarter worth $632,000. Steph & Co. raised its position in shares of Clover Health Investments by 33.3% in the fourth quarter. Steph & Co. now owns 20,000 shares of the company's stock worth $63,000 after buying an additional 5,000 shares in the last quarter. Finally, SignalPoint Asset Management LLC raised its position in shares of Clover Health Investments by 6.2% in the fourth quarter. SignalPoint Asset Management LLC now owns 160,074 shares of the company's stock worth $504,000 after buying an additional 9,390 shares in the last quarter. Hedge funds and other institutional investors own 19.77% of the company's stock.

Insider Activity at Clover Health Investments

In other Clover Health Investments news, General Counsel Karen Soares sold 52,500 shares of the stock in a transaction on Thursday, March 6th. The stock was sold at an average price of $3.80, for a total transaction of $199,500.00. Following the sale, the general counsel now owns 1,299,663 shares in the company, valued at $4,938,719.40. This represents a 3.88% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Carladenise Armbrister Edwards sold 200,000 shares of the stock in a transaction on Friday, March 7th. The stock was sold at an average price of $3.61, for a total value of $722,000.00. Following the sale, the director now owns 273,227 shares in the company, valued at approximately $986,349.47. This represents a 42.26% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 327,500 shares of company stock worth $1,197,500. Insiders own 22.28% of the company's stock.

Clover Health Investments Company Profile

Clover Health Investments, Corp. provides medicare advantage plans in the United States. It operates through two segments: Insurance and Non-Insurance. It also offers Clover Assistant, a cloud-based software platform, that enables physicians to detect, identify, and manage chronic diseases earlier; and access to data-driven and personalized insights for the patients they treat.